Moderna Inc. [NASDAQ: MRNA] jumped around 17.02 points on Tuesday, while shares priced at $282.35 at the close of the session, up 6.41%. The company report on December 1, 2021 that Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023.
Agreement includes 29 million doses for delivery in 2022 and 31 million doses for delivery in 2023.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced a revised supply agreement with the UK government for up to 60 million doses of Moderna’s COVID-19 vaccine, which may include authorized booster vaccine candidates, with up to 29 million doses expected to be delivered in 2022 and up to 31 million doses expected to be delivered in 2023. Under the agreement, the UK government retains a right to increase its purchases in 2022 and 2023 by up to 20% above the contracted volumes, or to decrease by the same amount.
Moderna Inc. stock is now 170.27% up from its year-to-date (YTD) trading value. MRNA Stock saw the intraday high of $287.77 and lowest of $263.07 per share. The company’s 52-week high price is 497.49, which means current price is +173.44% above from all time high which was touched on 08/10/21.
Compared to the average trading volume of 13.80M shares, MRNA reached a trading volume of 10695468 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Moderna Inc. [MRNA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $304.92 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cowen have made an estimate for Moderna Inc. shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on December 07, 2021. While these analysts kept the previous recommendation, Wolfe Research raised their target price to Outperform. The new note on the price target was released on November 09, 2021, representing the official price target for Moderna Inc. stock. Previously, the target price had yet another raise to $250, while Deutsche Bank analysts kept a Sell rating on MRNA stock.
The Average True Range (ATR) for Moderna Inc. is set at 28.17, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 9.51. The Price to Book ratio for the last quarter was 11.27, with the Price to Cash per share for the same quarter was set at 22.35. Price to Free Cash Flow for MRNA in the course of the last twelve months was 9.88 with Quick ratio for the last quarter at 1.30.
How has MRNA stock performed recently?
Moderna Inc. [MRNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -19.88. With this latest performance, MRNA shares gained by 19.14% in over the last four-week period, additionally plugging by 29.85% over the last 6 months – not to mention a rise of 77.00% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 47.08, with the RSI for the last a single of trading hit 46.64, and the three-weeks RSI is set at 46.72 for Moderna Inc. [MRNA]. The present Moving Average for the last 50 days of trading for this stock 307.02, while it was recorded at 293.30 for the last single week of trading, and 263.30 for the last 200 days.
Moderna Inc. [MRNA]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc. [MRNA] shares currently have an operating margin of -94.99 and a Gross Margin at +95.12. Moderna Inc.’s Net Margin is presently recorded at -92.99.
Return on Total Capital for MRNA is now -37.14, given the latest momentum, and Return on Invested Capital for the company is -36.66. Return on Equity for this stock declined to -39.99, with Return on Assets sitting at -16.74. When it comes to the capital structure of this company, Moderna Inc. [MRNA] has a Total Debt to Total Equity ratio set at 9.28. Additionally, MRNA Total Debt to Total Capital is recorded at 8.49, with Total Debt to Total Assets ending up at 3.24. Long-Term Debt to Equity for the company is recorded at 8.09, with the Long-Term Debt to Total Capital now at 7.41.
Reflecting on the efficiency of the workforce at the company, Moderna Inc. [MRNA] managed to generate an average of -$574,665 per employee. Receivables Turnover for the company is 1.13 with a Total Asset Turnover recorded at a value of 0.18.Moderna Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.30.
Earnings analysis for Moderna Inc. [MRNA]
With the latest financial reports released by the company, Moderna Inc. posted -0.69/share EPS, while the average EPS was predicted by analysts to be reported at -0.35/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -97.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Moderna Inc. go to 16.80%.
Insider trade positions for Moderna Inc. [MRNA]
There are presently around $69,301 million, or 61.20% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 42,217,354, which is approximately -7.99% of the company’s market cap and around 1.90% of the total institutional ownership; VANGUARD GROUP INC, holding 27,181,411 shares of the stock with an approximate value of $7.67 billion in MRNA stocks shares; and BLACKROCK INC., currently with $7.59 billion in MRNA stock with ownership of nearly 38.634% of the company’s market capitalization.
Positions in Moderna Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 708 institutional holders increased their position in Moderna Inc. [NASDAQ:MRNA] by around 42,024,067 shares. Additionally, 399 investors decreased positions by around 26,968,458 shares, while 94 investors held positions by with 176,452,339 shares. The mentioned changes placed institutional holdings at 245,444,864 shares, according to the latest SEC report filing. MRNA stock had 318 new institutional investments in for a total of 4,298,076 shares, while 74 institutional investors sold positions of 960,508 shares during the same period.